Company Overview
Highlights
Working with the National Institutes of Health to develop investigational pandemic influenza vaccines.
R&D partners include Avidia, Cerus Corporation, Micromet, and Xencor.
Established in 1988 by two former Army doctors, MedImmune is a biotechnology company that develops drugs for infectious disease, oncology, and immunology. The company partners with health care organizations involved in disease-management programs, information technologies, and clinical trials. MedImmune’s four products include Synagis (prevents respiratory tract infections), FluMist (a flu vaccine), CytoGam (suppresses viruses related to organ transplants), and Ethyol (reduces damage from chemotherapy). Its drug pipeline includes treatments for Epstein-Barr virus, cervical cancer, and non-Hodgkin’s lymphoma.